Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Obesity detrimental in ankylosing spondylitis

08 Oct 2020

Obesity is tied to adverse outcomes in ankylosing spondylitis (AS), including inflammation, disease activity, physical mobility, radiographic damage, health index, liver function, and cardiovascular risk factors, a study suggests.

The researchers looked at 105 AS patients (median age, 48 years; 87.6 percent male), of which 11 (10.5 percent) had diabetes and 19 (18.1 percent) had hypertension.

Twenty-nine patients were obese (body mass index [BMI] 27), 36 were overweight (24 BMI <27), and 40 were of normal weight (18.5 BMI <24). Using other anthropometric measures, there were 67 obese patients according to waist circumference (WC; 80 cm in women and 90 cm in men) and 77 according to waist-to-height ratio (WHtR; 0.5). WHtR defined the highest number of obese patients with AS.

Obesity (BMI, WC, and WHtR) had an unfavourable influence on inflammation (C‐reactive protein [CRP]), physical mobility (Bath Ankylosing Spondylitis Metrology Index), radiographic damage (modified Stoke Ankylosing Spondylitis Spinal Score [m-SASSS]), health index (Assessment of SpondyloArthritis International Society Health Index), liver function, and blood pressure (p<0.05 for all).

Likewise, central obesity, as defined by WC and WHtR, correlated with disease activity (Ankylosing Spondylitis Disease Activity Score‐CRP; p=0.027 and p=0.025) and predicted longitudinal radiographic change (m‐SASSS; p=0.041 and p=0.045).

Central obesity was the best predictor of inflammation, disease activity, physical mobility, radiographic damage, and health index in AS. On the other hand, WHtR was the best for predicting m‐SASSS (area under the curve, 0.734; p<0.001).

Obesity conferred an increased risk of diabetes and hypertension.

The findings highlight the importance of preventing obesity in AS patients to improve their disease outcome, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.